Tag Archives: PFE

Why MannKind’s Afrezza Will Succeed Where Pfizer Failed

Topnews, Worldnews, , ,

ByCory Renauer:

According to the American Diabetes Association, over 25 million people in the US alone have diabetes and the numbers keep on growing. Although insulin injections have come a long way, poking yourself with a needle in public still draws unwanted attention. MannKind Corporation (MNKD) is on the cusp of releasing an inhalable insulin treatment, Afrezza, that promises to revolutionize the way people treat this disease.

The Exubera Menace

Back in mid-2006, Pfizer (PFE) introduced an inhalable insulin treatment system created by Nektar Therapeutics (NKTR). Put mildly, it was a disaster. Just over a year after introducing the drug, Pfizer pulled the plug after losing about $2.8 billion on the flop.

The Exubera debacle still haunts MannKind, scaring away potential investors. What the market as a whole hasn’t considered is that although both the treatments involve an inhalable form or insulin, the similarities stop there.

Pfizer tried to market


Complete Story »

Cramer’s Mad Money – 16 Things To Watch In The Week Ahead (3/12/13)

Topnews, Worldnews, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

By SA Editor Miriam Metzinger:

Stocks discussed on the in-depth session of Jim Cramer’s Mad Money TV Program, Friday April 12.

16 Things To Watch In The Week Ahead: Citigroup (C), Google (GOOG), General Electric (GE), Intel (INTC), Microsoft (MSFT), Coca-Cola (KO), Johnson & Johnson (JNJ), Core Labs (CLB), Kinder Morgan Partners (KMP), The Gap (GPS), Union Pacific (UNP), Chipotle Mexican Grill (CMG), Honeywell (HON), Under Armour (UA), Kimberly Clark (KMB), McDonald’s (MCD). Other stocks mentioned: Pepsi (PEP), Barrick (ABX), BlackBerry (BBRY)

Earnings season revs up in the week ahead, and companies will indicate whether this miraculous rally is on borrowed time or is the real thing. Cramer would avoid trading around earnings, except for Google (GOOG) or General Electric (GE), a holding in Cramer’s charitable trust. If Intel’s (INTC) report is disappointing, and Microsoft (MSFT) declines to $27, those who are bullish on MSFT could buy some ahead of the earnings on Thursday.


Complete Story »

The Dow Weekly: 5 Cheapest Price-to-Book Stocks

Topnews, Worldnews, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

ByMichael Fu:

This is the second edition of the weekly series called The Weekly Dow (for last week’s article on the Top 5 Dividend Plays, click here). This week, we will look at the 5 cheapest Price-to-Book multiple stocks in the Dow Index Industrials Index (DIA). By the way, please reference my prior article on the pros and cons of looking at book value, specifically as it applies to bank and insurance stocks.

The 5 Cheapest P/B Stocks

As of April 9, 2013, the 5 cheapest P/B stocks in the Dow are Alcoa (AA) at 0.7x, Bank of America (BAC) at 0.9x, JP Morgan (JPM) at 1.2x, Travelers (TRV) at 1.3x and Verizon (VZ) at 1.7x.

Note that 3 of these stocks (BAC, JPM and TRV) are bank and insurance stocks. Note that bank stocks and insurance stocks are levered, and the financial assets that are held on their balance


Complete Story »

2 Stocks To Buy, 1 Stock To Sell, What’s Next For The Market

Topnews, Worldnews, , , ,

By The Oxen Group:

Market Outlook:

For Friday, the market all boils down to Non-farm Payrolls and the Unemployment Rate. After a weak ADP Employment Change number on Wednesday followed by stronger than expected Initial Jobless Claims on Thursday, Friday’s NFP report will be very important to market direction for the day and likely next week. At the same time, the weak move on Wednesday for the markets likely priced in some expectations of a miss for Friday’s report.

Additionally, the positive news from the Bank of Japan to introduce a new monetary policy similar to the Fed’s QE helped markets rally Thursday. That news should help balance weakness in employment as well. Therefore, we would look for a hushed move lower on any weakness in NFP and a very positive reaction if NFP surprises and comes close to expectations or beats them. Look for a 20-40 point drop on the Dow Jones (DIA)


Complete Story »

Wall Street Breakfast: Must-Know News

Topnews, Worldnews, , , , , , , , , , , , , , , ,

Wall Street Breakfast Editors submit:

Top Stories
Nikkei soars as BOJ launches blitzkrieg on deflation. The Nikkei (NKY) surged and the yen (FXY) plummeted after the Bank of Japan defied all expectations in its battle to end deflation. Following its first policy meeting under new Governor Haruhiko Kuroda, the BOJ will change its target when setting policy from the overnight call rate to the monetary base, which the bank aims to double within two years by purchasing ¥60-70T of assets a year. These include government bonds of all maturities and not just short-term debt. The plan is open-ended, and, significantly, was unanimously approved. The dollar was +2.6% vs the yen at the time of writing.

Eurozone service sector remains in the mire. Eurozone composite PMI dropped to 46.5 in March from 47.9 in February, with the services index slipping to 46.4 from 47.9. "The recession is deepening once again as businesses report


Complete Story »

Wall Street Breakfast: Must-Know News

Topnews, Worldnews, , , , , , , , , , , , , ,

Wall Street Breakfast Editors submit:

Top Stories
Eurozone inflation drops further away from ECB’s target. As expected, eurozone inflation dropped to an annual rate of 1.7% in March from 1.8% in February, falling further away from the ECB’s target of just under 2%. Given the fairly poor state of the eurozone economy, the decline in prices could provide scope for the ECB to ease monetary policy further when officials meet tomorrow, although it’s not expected to cut interest rates from the current level of 0.75%.

DJIA, S&P eye further highs. The Dow Jones and the S&P 500 look set to add to their record finishes yesterday, with U.S. stock futures higher in pre-market trading despite shares in Europe falling. The continued bull run in the U.S. came as health insurers rallied on positive Medicare reimbursement news and as U.S. factory orders rose in February. ADP is due to issue its March report today,


Complete Story »

Pfizer’s Dividend Looks Safe, But Little Growth Lies Ahead

Topnews, Worldnews,

By Valuentum:

Dividend growth investing is lots of fun, especially if you have a systematic methodology to determining which companies’ dividends are safe and which aren’t. That is why we created a forward-looking assessment of dividend safety in our innovative, predictive dividend-cut indicator, the Valuentum Dividend Cushion™. In this article, let’s evaluate the investment merits of Pfizer (PFE), as well as its dividend under this unique but yet very straightforward framework.

Investment Considerations

Return on Invested Capital

Pfizer’s Dividend


(click to enlarge)

Pfizer’s dividend yield is excellent, offering just under a 4% annual payout at recent price levels. We prefer yields above 3% and don’t include firms with yields below 2% in our dividend growth portfolio. So Pfizer fits the bill thus far.

We think the safety of Pfizer’s dividend is good (please see our definitions at the bottom of this article). We measure the safety of the dividend in a unique


Complete Story »

The Perfect Portfolio, Evolved

Topnews, Worldnews, , , , , , , , , , , , , , , , , , , , , ,

ByRy The Kid:

The last article I wrote received many positive yet mixed reviews, and some readers viewed some holdings are redundant in certain sectors. Many constructive comments were made, and the one that stuck with me was that a truly great portfolio is one that evolves with time. Comments were also made about being overly conservative by only buying near 52-week lows, which some companies rarely hit. I would still like to only buy stock in a company if it is trading below the midpoint of its 52-week range, but that is not a deal breaker for me anymore. However, I stand by my philosophy that being truly diversified doesn’t mean owning companies from every sector in the market. I still think some sectors can be omitted, while maintaining diversity and the portfolio’s overall goal, a rising income stream. This can be achieved while maintaining a low beta, a healthy payout


Complete Story »